Target intelligence / Profile preview

Removing Blood Stasis

01

Overview

Removing Blood Stasis (Huoxue Huayu) is a fundamental therapeutic principle in Traditional Chinese Medicine (TCM) used to treat conditions characterized by impaired blood flow, fixed pain, or abnormal masses [World Journal of Traditional Chinese Medicine, 2020]. It is not a single molecular target, receptor, or enzyme, but rather a pharmacological category that encompasses a wide range of biological activities aimed at restoring normal circulation. Modern pharmacological research indicates that herbs and formulas with this property exert their effects through multiple molecular pathways, such as inhibiting platelet aggregation, promoting fibrinolysis, and improving endothelial function [PubMed: 30553153]. Common clinical applications include the treatment of cardiovascular diseases, stroke, and chronic inflammatory conditions. Because it represents a broad therapeutic strategy rather than a specific protein or gene, it cannot be classified as a discrete molecular target in the conventional drug discovery sense.

Other names
Huoxue HuayuActivating blood circulation and removing blood stasisPromoting blood circulation to dissipate blood stasisBlood-stasis-removing therapy
02

Mechanism of action

This is a therapeutic principle in Traditional Chinese Medicine (TCM) rather than a single molecular mechanism. It involves multi-target effects including the inhibition of platelet activation (via TXA2/PGI2 balance), reduction of blood viscosity, modulation of the coagulation cascade, and improvement of endothelial function [PubMed: 28655521, Frontiers in Pharmacology 2019].

03

Biological functions

AnticoagulationAnti-platelet aggregationVasodilationImprovement of microcirculationFibrinolysisAnti-inflammation
04

Disease associations

Cardiovascular diseaseCerebrovascular diseaseThrombosisChronic inflammationFibrosisEndometriosisDysmenorrhea
05

Safety considerations

Increased risk of hemorrhage or bleedingDrug-drug interactions with conventional anticoagulants and antiplatelet agentsContraindicated during pregnancy due to risk of miscarriagePotential for menorrhagia
06

Interacting drugs

Salvia miltiorrhiza (Danshen)

6 more in the full profile.

07

Biomarkers

D-dimerFibrinogen (FIB)Platelet aggregation rateWhole blood viscosityProthrombin time (PT)Activated partial thromboplastin time (aPTT)

Beyond the preview

Go deeper on Removing Blood Stasis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Removing Blood Stasis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call